Canopy Growth Corp

Canopy Growth Corporation operates in the global cannabis industry, producing, distributing, and selling cannabis and cannabis-related products for adult-use and medical purposes. The company supplies products in Canada, Europe, and Australia, and holds a significant non-controlling, non-voting interest in Canopy USA, which participates in the U.S. cannabis market. The filing describes the industry as a global economic force in the making, with the potential to rival the largest consumer packaged goods industries.

The filing names several competitors implicitly through market context but does not provide a list of primary competitors or specific market share percentages. Management states that Canopy Growth is a world-leading cannabis company and expects to continue to be Canada's number one medical cannabis provider by revenue. The company emphasizes its competitive advantages in brand portfolio, cultivation quality, and international medical cannabis distribution.

Canopy Growth generates revenue through the production, distribution, and sale of cannabis and cannabis-related products for adult-use and medical purposes. Revenue streams include dried flower, pre-rolled joints, oils, softgel capsules, edibles including gummies, vapes, and cannabis accessories such as vaporizer devices. The company serves medical cannabis patients and adult-use consumers, with a portfolio of distinct brands in Canada and internationally under applicable legislation and permits.

The company's cannabis product categories include dried flower, pre-rolled joints, extracts and concentrates, cannabis edibles including gummies, and cannabis vapes. Dried flower is described as the core of all cannabis markets globally. The extracts and concentrates category includes softgel capsules and hash, with hash noted as a market leader for consistency, texture, and potency. Cannabis edibles are viewed as a major long-term growth driver. Vape cartridges are tested to the FDA standard for leachability, and all-in-one vape products are produced using UL 8139 or equivalent Certified Safe Manufacturing standards. Through Storz & Bickel, the company manufactures and sells medical cannabis and dry herb vaporizer devices, including the Volcano Medic 2 and Mighty+ Medic, which hold registrations in Australia, Canada, the European Union, Israel, Switzerland, and the United Kingdom. On September 9, 2025, Storz & Bickel launched the Veazy, the first vaporizer from Storz & Bickel available in multiple colors.

The company's brand portfolio includes adult-use brands Tweed, DOJA, 7ACRES, DeeLish, Deep Space, MTL Cannabis, HiWay, LowKey by MTL Cannabis, Maitri, R'belle, and Twd. Medical brands include Spectrum Therapeutics in Canada and Canopy Medical in select international markets. The company also holds affiliated brands licensed from others. The medical platform is anchored by Spectrum Therapeutics and Canopy Medical, built on standards of safety, consistency, and efficacy.

During the fiscal year ended March 31, 2026, Canopy Growth completed the acquisition of MTL Cannabis Corp. The company also created Canopy USA, LLC to accelerate entry into the U.S. cannabis market. Canopy USA acquired Lemurian, Inc. (Jetty) through the exercise of options, with a final tranche closing pending. The company entered into a Trust Transaction involving the issuance of warrants of Canopy USA to the Trust. Canopy Growth also entered into a loan agreement on January 8, 2026, for a secured debt facility. The company made paydowns on its credit facility during the fiscal year, including an early prepayment on September 12, 2025. The company issued common shares through at-the-market equity programs, including a February 2025 program and an August 2025 program with a maximum authorization. The company also completed a unit offering in January 2024 and a unit offering in September 2023. The company settled convertible debentures and exchanged debt with Supreme Cannabis. The company divested ThisWorks in December 2023.

For the fiscal year ended March 31, 2026, total net revenue was not explicitly stated in a single headline figure in the filing's business overview section, but the financial statements show total net revenue of C$23.486 billion for the fiscal year ended March 31, 2026, compared to C$680.985 billion for the fiscal year ended March 31, 2025. Net loss for the fiscal year ended March 31, 2026 was C$22.270 billion, compared to a net loss of C$26.356 billion for the fiscal year ended March 31, 2025. Basic and diluted net loss per share was C$2.73 for the fiscal year ended March 31, 2026, compared to C$2.41 for the fiscal year ended March 31, 2025.

One major growth vector is the international medical cannabis market. The company delivers medical cannabis to patients in Germany, Poland, and Australia and expects to do so in the United Kingdom over the coming fiscal year. The company intends to fuel demand for EU-GMP certified medical grade cannabis with supply from within Europe and from its Canadian EU-GMP certified facility in Kincardine, Ontario. Another growth vector is the U.S. cannabis market through Canopy USA, which provides a unique opportunity to maximize the value of previously-held conditional U.S. THC investments. The company continues to explore brand opportunities to build a foundation for indirect participation in the U.S. market.

The filing does not provide specific margin or cost trajectory targets with exact figures. Management discusses a disciplined 'asset-right' model focused on driving efficiency for the greatest return on asset investments, but no numerical margin or cost targets are stated.

The company's operational outlook includes optimizing its operating footprint to achieve profitability and foster growth while retaining commitment to product quality and supply chain integrity. The company has access to world leading genetics and talent through the MTL acquisition to shape cultivation practices. The company intends to make selective investments in assets that will accelerate returns and secure long-term sustainable profitability, and will continue to leverage local and/or regional suppliers for raw materials.

The filing does not provide specific R&D spending levels, capital expenditure plans, share repurchase authorization amounts, or dividend policy figures for the upcoming period. The company has at-the-market equity programs, including an August 2025 program, but no specific future spending amounts are disclosed.

The filing identifies several headwinds and constraints. These include the risk that the company may be required to write down intangible assets, including goodwill, due to impairment. The company also faces risks related to the overall macroeconomic environment, which may impact customer spending, costs, and margins, including tariffs, inflation, interest rates, and trade policy. The evolving regulatory landscape in the United States is identified as a constraint, particularly regarding the rescheduling of medical cannabis and the uncertainty of federal legalization. The company also notes risks related to the ability of Acreage and Wana to satisfy their debt obligations as they become due.

The filing identifies additional constraints including the volatility in general economic, market, industry, or business conditions, and the risks relating to the company's current and future operations in emerging markets. The company also faces risks from compliance with environmental, economic, health and safety, energy, and other policies and regulations, particularly health concerns with respect to vaping and the use of cannabis products in vaping devices.

The company faces material risks including the potential inability to achieve or maintain profitability and the possibility of continuing losses. The company has identified conditions and events that raised substantial doubt about its ability to continue as a going concern in the past, and it is possible such conditions may arise again. The company may be required to write down intangible assets, including goodwill, due to impairment, which could materially affect financial results. The anticipated benefits of the Canopy USA strategy may not be realized, and the fair value of the equity method investment in Canopy USA is volatile. The company is subject to extensive regulation and licensing, and failure to comply with all applicable laws and regulations could have a material adverse effect. The company has identified a material weakness in internal control over financial reporting, which could adversely affect the ability to report financial condition and results of operations accurately and on a timely basis. The company is the subject of a regulatory investigation and inquiry in connection with the BioSteel Review, and any adverse outcome could have a material adverse effect. In the event Acreage or Wana cannot satisfy their debt obligations, the Acreage and Wana Debt may not be repaid, and the company may lose the entirety of its investment in that debt, negatively impacting Canopy USA's business and the company's U.S. strategy.

Management's message emphasizes a vision to better lives through cannabis and a strategy to build a global, consumer-centric company. Key themes include leadership in the Canadian medical cannabis market, global vaporization through Storz & Bickel, focused growth in international medical cannabis, profitable scale in adult-use cannabis through powerhouse brands, a disciplined 'asset-right' model, and unparalleled exposure to the U.S. cannabis market through Canopy USA. Management states the company expects to continue to be Canada's number one medical cannabis provider by revenue. The strategic priorities emphasized are: being Canada's number one medical cannabis provider by revenue, leadership of global vaporization through Storz & Bickel, focused growth in international medical cannabis markets, focusing on profitable scale in adult-use cannabis through powerhouse brands, leveraging the disciplined 'asset-right' model to build world class cultivation, and maintaining unparalleled exposure to the expanding U.S. cannabis market.